| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6726918 | ABBVIE | Methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9283178 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US9012437 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US8088407 | ABBVIE | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US9775849 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US8063031 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9592242 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US8043628 | ABBVIE | Methods for reducing edema |
Oct, 2020
(3 years ago) | |
| US7767223 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
Nov, 2021
(2 years ago) | |
| US10702539 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8034370 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US10076526 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8034366 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US9192511 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8506987 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US6899717 | ABBVIE | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(5 months ago) | |
Ozurdex is owned by Abbvie.
Ozurdex contains Dexamethasone.
Ozurdex has a total of 17 drug patents out of which 17 drug patents have expired.
Expired drug patents of Ozurdex are:
- US6726918
- US9283178
- US9012437
- US8088407
- US9775849
- US8063031
- US9592242
- US7033605
- US8043628
- US7767223
- US10702539
- US8034370
- US10076526
- US8034366
- US9192511
- US8506987
- US6899717
Ozurdex was authorised for market use on 17 June, 2009.
Ozurdex is available in implant;intravitreal dosage forms.
Ozurdex can be used as intravitreal treatment of diabetic macular edema, treatment of uveitis, treatment of non-infectious uveitis affecting the posterior segment of the eye, treatment of macular edema, delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex.
The generics of Ozurdex are possible to be released after 01 November, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2012 |
| New Indication(I-686) | Jun 29, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2017 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of macular edema; Intravitreal treatment of diabetic macular edema; Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of uveitis; Delivering an ocular...
Dosage: IMPLANT;INTRAVITREAL
OZURDEX family patents
